Biohaven Future Growth

Future criteria checks 2/6

Biohaven is forecast to grow earnings and revenue by 21.6% and 70.9% per annum respectively. EPS is expected to grow by 28% per annum. Return on equity is forecast to be -119.6% in 3 years.

Key information

21.6%

Earnings growth rate

28.0%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate70.9%
Future return on equity-119.6%
Analyst coverage

Good

Last updated14 Nov 2024

Recent future growth updates

Recent updates

Biohaven: A Complicated Tale

Oct 11

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Sep 23

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Jul 26

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

May 18

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Apr 06
We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Mar 01
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Feb 28

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Dec 08

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Dec 04
Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Sep 27

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Aug 28

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Jul 22
Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: A Promising Investment In Innovative Neurological Therapies

Jun 14

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Jun 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Apr 06
Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

Feb 21

Biohaven Ltd: Assessing The Spinoff

Dec 07

Biohaven Non-GAAP EPS of -$1.25

Nov 09

Earnings and Revenue Growth Forecasts

NYSE:BHVN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026187-627-629-51110
12/31/202521-668-614-54413
12/31/20248-814-830-53612
9/30/2024N/A-804-531-527N/A
6/30/2024N/A-747-485-480N/A
3/31/2024N/A-517-359-357N/A
12/31/2023N/A-408-335-332N/A
9/30/2023N/A-465-295-292N/A
6/30/2023N/A-431-299-293N/A
3/31/2023N/A-544-323-316N/A
12/31/2022N/A-570-304-298N/A
9/30/2022N/A-421-261-255N/A
6/30/2022N/A-407-205-204N/A
3/31/2022N/A-257-171-170N/A
12/31/2021N/A-214-147-146N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BHVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BHVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BHVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BHVN's revenue (70.9% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: BHVN's revenue (70.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BHVN is forecast to be unprofitable in 3 years.


Discover growth companies